Skip to main content

Advertisement

SpringerLink
Log in

Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Single-institution single-arm prospective study. Endpoint: To assess whether there are more than 5 % of men having grade 3 GU or any grade 3 GI acute toxicity during stereotactic body radiation therapy (SBRT) for prostate cancer using helical tomotherapy.

Methods

Since May 2012, 17 prostate cancer patients were treated with helical tomotherapy. The exclusion criteria used are the following: Gleason score ≥8, PSA >20 ng/ml, cT3b-4, IPSS ≥20 and history of acute urinary retention. CTV included the prostate gland and 1 cm of seminal vesicles in the low-risk group (LR) or the seminal vesicles completely in the intermediate (IR) and high-risk (HR) NCCN groups. CTV margins ranged from 2 to 8 mm, while PTV margins were 2 to 9 mm. Patients received eight fractions of 5.48 Gy (LR) or 5.65 Gy (IR, HR) on alternate days. Total equivalent doses at 2 Gy per fraction are 87.4 for LR and 92.3 Gy for IR–HR using an α/β value of 1.5. Correspondent figures for a α/β of 3 are 74.3 Gy and 78.2 Gy, respectively. Megavoltage CT (MVCT) for on-line correction was taken before every fraction.

Results

The patient distribution by risk group is 29, 47 and 24 % for LR, IR and HR, respectively. 82 % received neoadjuvant-concomitant hormonal therapy. Acute GU toxicity grade 1, 2 and 3 was found in 70, 6 and 0 % of men. GI toxicity was observed in 50, 0 and 0. After 136 MVCT, the standard deviation of the mean individual corrections in the anterior–posterior direction was 2.5 mm.

Conclusion

SBRT for prostate cancer using helical tomotherapy is feasible. Initial results show an early toxicity profile no worse than SBRT delivered with robotic radiosurgery or conventionally fractionated radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43(5):1095–101.

    Article  CAS  PubMed  Google Scholar 

  2. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;56(4):1093–104.

    Article  PubMed  Google Scholar 

  3. Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1072–83.

    Article  PubMed  Google Scholar 

  4. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23(25):6132–8.

    Article  PubMed  Google Scholar 

  5. Pollack A. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. In: International Journal of Radiation Oncology Biology and Physics. http://www.redjournal.org/article/S0360-3016(11)00824-8/fulltext. Accessed 04 Apr 2013.

  6. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11–8.

    Article  PubMed  Google Scholar 

  7. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13(1):43–54.

    Article  PubMed  Google Scholar 

  8. Macías V, Biete A. Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol. 2009;11(7):437–45.

    Article  PubMed  Google Scholar 

  9. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043–8.

    Article  PubMed  Google Scholar 

  10. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877–82.

    Article  PubMed  Google Scholar 

  11. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009;8(5):387–92.

    CAS  PubMed  Google Scholar 

  12. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118(15):3681–90.

    Article  PubMed  Google Scholar 

  13. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013;8(1):58.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3–9.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Study Number 0415. In: RTOG. Clinical trials. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0415. Accessed 04 Apr 2013.

  16. Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, et al. Dose–volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 2010;76(3):747–54.

    Article  PubMed  Google Scholar 

  17. Katz A, Freeman D, Aronovitz J, Fuller D, Bolzicco G, Meier R, et al. Five-year biochemical control rates for stereotactic body radiation therapy for organ-confined prostate cancer: a multi-institutional pooled analysis. Int J Radiat Oncol Biol Phys. 2012;84(3):S147–8.

    Article  Google Scholar 

  18. Katz A. Stereotactic body radiation therapy offers a safe, non-invasive treatment for prostate cancer patients over 70 years old. Int J Radiat Oncol Biol Phys. 2012;84(3):S361.

    Article  Google Scholar 

  19. Mantz CA, Fernandez E. Real-time target tracking prostate SBRT: quality of life and disease outcomes from a phase II trial. Int J Radiat Oncol Biol Phys. 2012;84(3):S368.

    Article  Google Scholar 

  20. Kim CH, Beriwal S, Benoit RM, Houser C, Smith RP. Is there a secondary spike in urinary symptoms with Cs131 prostate brachytherapy? A longitudinal analysis with patient reported epic survey and AUA score. Int J Radiat Oncol Biol Phys. 2012;84(3):S416–7.

    Google Scholar 

  21. Katz A, Ferrer M, Suárez JF. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. Radiat Oncol. 2012;7:194.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Mak RH, Hunt D, Shipley WU, Jones CU, Lukka HR, Bahary JP, et al. Acute and late urinary toxicity after radiation therapy in men with and without an intact prostate gland: a secondary analysis of RTOG 9408 and 9601 suggesting this toxicity is not due to bladder injury. Int J Radiat Oncol Biol Phys. 2012;84(3):S14.

    Article  Google Scholar 

  24. Macias V, Gonzalez Celador R, Marti-Macia C, Cigarral C, Perez-Romasanta LA. Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy. Clin Transl Oncol. 2013;86(4):709–15.

    Google Scholar 

  25. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71(4):1028–33.

    Article  PubMed  Google Scholar 

  26. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424–30.

    Article  PubMed  Google Scholar 

  27. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67(4):1099–105.

    Article  PubMed  Google Scholar 

  28. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie X-J, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29(15):2020–6.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol). 2008;20(10):729–37.

    Article  CAS  PubMed  Google Scholar 

  30. Menkarios C, Vigneault É, Brochet N, Nguyen DHA, Bahary J-P, Jolicoeur M, et al. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial. Radiat Oncol. 2011;6:112.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Radiation Oncology, Salamanca University Hospital, Paseo de San Vicente, 182, 37007, Salamanca, Spain

    V. A. Macias, M. L. Blanco & L. A. Perez-Romasanta

Authors
  1. V. A. Macias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. L. Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. A. Perez-Romasanta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. A. Macias.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macias, V.A., Blanco, M.L. & Perez-Romasanta, L.A. Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy. Clin Transl Oncol 16, 380–385 (2014). https://doi.org/10.1007/s12094-013-1089-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1089-y

Keywords

Search

Navigation